Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemoradiation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    197 result(s) found for: Chemoradiation. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-003237-41 Sponsor Protocol Number: MK-7339-012 Start Date*: 2020-06-23
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by ...
    Medical condition: unresectable, locally advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) HU (Trial now transitioned) LV (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) EE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) RO (Trial now transitioned) IT (Trial now transitioned) LT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018327-26 Sponsor Protocol Number: 20080686 Start Date*: 2010-06-09
    Sponsor Name:VU University Medical Center
    Full Title: Chemoradiation with gemcitabine in combination with panitumumab for patients with locally advanced pancreatic cancer.
    Medical condition: Inoperable locally advanced pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-003906-81 Sponsor Protocol Number: A7-2 Start Date*: 2005-01-14
    Sponsor Name:Oncology Institute of Vilnius University
    Full Title: Chemoradiation with once weekly gemcitabine for invasive bladder cancer
    Medical condition: Invasive transitional cell bladder cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004111-42 Sponsor Protocol Number: TRAP Start Date*: 2014-03-11
    Sponsor Name:Academic Medical Center
    Full Title: Feasibility study of chemoradiation, TRAstuzumab and Pertuzumab in resectable HER2+ esophageal carcinoma
    Medical condition: Esophageal carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002079-36 Sponsor Protocol Number: 73750 Start Date*: 2020-10-20
    Sponsor Name:Amsterdam University Medical Centers
    Full Title: TGF-β And PDL-1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY)
    Medical condition: Esophageal squamous cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006068-32 Sponsor Protocol Number: CDX110-04 Start Date*: 2012-07-04
    Sponsor Name:Celldex Therapeutics, Inc
    Full Title: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma ...
    Medical condition: Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Completed) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001534-13 Sponsor Protocol Number: JAN13004-30 Start Date*: 2015-10-02
    Sponsor Name:SPHERIUM BIOMED S.L.
    Full Title: Phase IB-II clinical trial of melatonin oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing chemoradiation.
    Medical condition: Oral mucositis in patients with head and neck cancer undergoing chemoradiation
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022117 - Injury, poisoning and procedural complications 10037763 Radiation mucositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005177-29 Sponsor Protocol Number: EORTC 26052-22053 Start Date*: 2006-11-10
    Sponsor Name:EORTC
    Full Title: Phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma
    Medical condition: Patients with Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) FR (Completed) LV (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2018-000626-60 Sponsor Protocol Number: UC-0130/1804 Start Date*: 2019-01-08
    Sponsor Name:UNICANCER
    Full Title: A multicenter, randomized, open label, phase II study evaluating the feasibility and tolerance of nivolumab neoadjuvant immunotherapy in high risk HPV driven Oropharynx Cancer.
    Medical condition: High risk Human Papilloma Virus (HPV)-driven oropharynx cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004744-11 Sponsor Protocol Number: PERFECT Start Date*: 2017-02-27
    Sponsor Name:Academic Medical Center
    Full Title: PDL-1 targeting in resectable oesophageal cancer: a phase IB feasibility study of Atezolizumab and chemoradiation (PERFECT)
    Medical condition: oesophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001061-16 Sponsor Protocol Number: D5160C00048 Start Date*: 2018-09-04
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of Osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-posit...
    Medical condition: Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004030-40 Sponsor Protocol Number: TOGA 0502 Start Date*: 2006-02-06
    Sponsor Name:Thoracale Oncologie Groep Antwerpen
    Full Title: A RANDOMIZED MULTICENTER PHASE II STUY OF INDUCTION THERAPY WITH PEMETREXED AND CISPLATIN FOLLOWED BY CHEMORADIATION WITH PEMETREXED VERSUS CHEMORADIATION WITH PEMETREXED FOLLOWED BY CONSOLIDATION ...
    Medical condition: Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001098-15 Sponsor Protocol Number: CCRG14-001 Start Date*: 2015-10-13
    Sponsor Name:Antwerp University Hospital
    Full Title: Adjuvant dendritic-cell immunotherapy plus temozolomide following surgery and chemoradiation in patients with newly diagnosed glioblastoma
    Medical condition: Newly diagnosed glioblastoma (WHO grade IV) in adults, treated with surgical resection and chemoradiation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001300-35 Sponsor Protocol Number: UCL11/0034 Start Date*: 2012-01-31
    Sponsor Name:University College London
    Full Title: A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer
    Medical condition: Locally advanced cervical cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008233 Cervical cancer stage I LLT
    21.1 100000004864 10008234 Cervical cancer stage II LLT
    21.1 100000004864 10008235 Cervical cancer stage III LLT
    21.1 100000004864 10008236 Cervical cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002272-14 Sponsor Protocol Number: CDX110-07 Start Date*: 2013-01-11
    Sponsor Name:CELLDEX THERAPEUTICS
    Full Title: An International, Randomized, Double-Blind, Controlled Phase II Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glio...
    Medical condition: Newly diagnosed, surgically resected, EGFRvIII-positive Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004161-68 Sponsor Protocol Number: AG013-ODOM-201 Start Date*: 2018-10-31
    Sponsor Name:Oragenics, Inc.
    Full Title: A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cance...
    Medical condition: Oral mucositis (OM) induced by chemoradiation therapy (CRT) used for the treatment of head and neck cancers (HNC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-000355-37 Sponsor Protocol Number: MEC-2022-0373 Start Date*: 2022-08-29
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study
    Medical condition: Operable patients ≥ 18 years of age with locoregionally advanced squamous cell- or adenocarcinoma of the esophagus or esophagogastric junction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006646-34 Sponsor Protocol Number: ERA-GASTRO-ONCO-001 Start Date*: 2007-03-13
    Sponsor Name:Erasme Hospital - Department of Gastroenterology
    Full Title: OXALIPLATIN PLUS 5-FLUOROURACIL BASED-CHEMOTHERAPY INDUCTION FOLLOWED BY PREOPERATIVE CHEMORADIATION VERSUS PREOPERATIVE CHEMORADIATON ALONE IN ADVANCED RECTAL ADENOCARCINOMA: RANDOMIZED CONTROLLED...
    Medical condition: advanced rectal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038028 Rectal adenocarcinoma stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008209-22 Sponsor Protocol Number: AMC002 Start Date*: 2009-02-25
    Sponsor Name:Academic Medical Center
    Full Title: Chemoradiation combined with panitumumab followed by surgery for patients with operable esophageal cancer
    Medical condition: Surgical resectable: T2-3, N0-1, M0 adenocarcinomas, undifferentiated or squamous cell carcinomas of the esophagus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006120-36 Sponsor Protocol Number: N07CRH Start Date*: 2009-01-07
    Sponsor Name:
    Full Title: Phase I/II Study of Combined Treatment with AT-101, Cisplatin and Radiotherapy in Patients with Locally Advanced Head and Neck Cancer
    Medical condition: advanced HNSCC
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 07 14:59:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA